Skip to content
Clinical Trials – home

PARACETAMOL PH. EUR.: A Comprehensive Guide for Patients

2 / 8
trials open to patients / all trials
14+
Countries

In short

This article explores the use of Paracetamol Ph. Eur. in clinical trials for a range of medical conditions. Paracetamol, also known as acetaminophen, is a common pain reliever and fever reducer. The clinical trials discussed here investigate its potential applications in different therapeutic areas, from cancer to rheumatoid arthritis. These studies aim to assess the safety and efficacy of Paracetamol Ph. Eur. when used alone or in combination with other treatments.

At a glance

Medical Conditions Studied
Multiple myeloma, chronic pain due to diabetic polyneuropathy, acute myocardial infarction, mantle cell lymphoma, Hodgkin and non-Hodgkin lymphoma, rheumatoid arthritis
Administration Routes
Oral, intravenous, and other routes as specified by individual trials
Dosage Range
Varies by trial, from 500 mg to 4000 mg daily
Trial Durations
Range from a few weeks to over 52 weeks
Primary Objectives
Evaluate safety, efficacy, pharmacokinetics, and combination therapy potential
Key Endpoints
Pain reduction, disease progression, quality of life improvements, adverse event monitoring
Patient Demographics
Adults (typically 18 years and older), with specific age ranges varying by study
Combination Therapies
Used alone or in combination with other drugs such as rituximab, certolizumab, and various cancer therapies

What is PARACETAMOL PH. EUR.?

PARACETAMOL PH. EUR. is a common pain reliever and fever reducer. It is also known by other names such as acetaminophen or APAP. The "PH. EUR." in the name stands for "European Pharmacopoeia," which refers to the official standards for medicine quality in Europe.

This medication belongs to a class of drugs called analgesics (pain relievers) and antipyretics (fever reducers). It works by changing the way your body senses pain and by cooling the body.

What is PARACETAMOL PH. EUR. used for?

PARACETAMOL PH. EUR. is commonly used to treat a variety of conditions, including:

  • Mild to moderate pain (such as headaches, toothaches, menstrual cramps, and backaches)
  • Fever reduction
  • Cold and flu symptoms
  • Arthritis pain

In some cases, it may be used in combination with other medications to treat more severe pain or as part of a treatment plan for chronic conditions.

How is PARACETAMOL PH. EUR. taken?

The dosage of PARACETAMOL PH. EUR. can vary depending on the specific product and the condition being treated. However, some general guidelines include:

  • For adults: The typical dose is 500-1000 mg every 4-6 hours, not exceeding 4000 mg in 24 hours.
  • For children: Dosage is usually based on weight and age. Always follow the instructions provided by your healthcare provider or on the product label.

It's important to note that PARACETAMOL PH. EUR. can be taken orally in various forms, including tablets, capsules, or liquid formulations. Some formulations may also be administered intravenously in hospital settings.

What are the potential side effects?

While PARACETAMOL PH. EUR. is generally considered safe when used as directed, it can cause side effects in some people. Common side effects may include:

  • Nausea
  • Stomach pain
  • Headache
  • Skin rash or itching

In rare cases, more serious side effects can occur, especially with high doses or long-term use. These may include liver damage or allergic reactions. If you experience any unusual symptoms, contact your healthcare provider immediately.

Precautions and warnings

While PARACETAMOL PH. EUR. is widely used, there are some important precautions to keep in mind:

  • Liver disease: People with liver problems should use caution and consult their doctor before taking this medication.
  • Alcohol use: Drinking alcohol while taking paracetamol can increase the risk of liver damage.
  • Other medications: Inform your healthcare provider about all medications you're taking, as paracetamol can interact with certain drugs.
  • Pregnancy and breastfeeding: While generally considered safe, consult your doctor before use if you're pregnant or breastfeeding.

It's crucial to follow the recommended dosage and not exceed the maximum daily dose to avoid potential liver damage.

Ongoing research

While PARACETAMOL PH. EUR. is a well-established medication, research continues to explore its potential uses and effects. Some ongoing studies are investigating its use in combination with other drugs for various conditions, including:

  • Rheumatoid arthritis: A study is exploring the use of paracetamol alongside other medications for patients with active rheumatoid arthritis.
  • Cancer-related pain: Research is being conducted on the use of paracetamol as part of pain management strategies in cancer patients.
  • Cardiovascular conditions: Some studies are investigating the potential role of paracetamol in patients with certain heart conditions.

These ongoing studies may provide new insights into the potential benefits and applications of PARACETAMOL PH. EUR. in various medical contexts.

Questions people often ask

Conditions where Paracetamol Ph. Eur. is being studied

Each condition opens its own overview and trial list

Trials with Paracetamol Ph. Eur.

Recruiting trials first

See all 8 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).